Cargando…

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib

Immune thrombocytopenia (ITP) is immune-mediated platelet loss due to increased destruction and insufficient production. Treatment guidelines provide for first-line steroid-based therapies followed by thrombopoietin receptor agonists (TPO-RAs) and fostamatinib for chronic ITP. Fostamatinib demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Innao, Vanessa, Calogero, Rosalba Donatella, Lo Presti, Fabrizio, Consoli, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266907/ https://www.ncbi.nlm.nih.gov/pubmed/37323813 http://dx.doi.org/10.1155/2023/9953245

Ejemplares similares

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
por: Cooper, Nichola, et al.
Publicado: (2021)

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
por: Lucchesi, Alessandro, et al.
Publicado: (2023)

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
por: Bussel, James, et al.
Publicado: (2018)

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
por: Bussel, James B., et al.
Publicado: (2019)

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series
por: Liu, Jessica, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia
por: Mallat, Ziad, et al.
Publicado: (2021)

Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation
por: Innao, Vanessa, et al.
Publicado: (2022)

Treatment of drug-induced immune thrombocytopenias
por: Marini, Irene, et al.
Publicado: (2022)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

Treatment of inherited thrombocytopenias
por: Balduini, Carlo L.
Publicado: (2022)

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
por: Lengel, Dave, et al.
Publicado: (2015)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
por: Herman, SEM, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
por: Mancuso, Salvatrice, et al.
Publicado: (2020)

Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
por: Zhao, Shasha, et al.
Publicado: (2021)

Refractory immune thrombocytopenia: Lessons from immune dysregulation disorders
por: Costagliola, Giorgio, et al.
Publicado: (2022)

Case report. Thrombus formation on left atrial appendage clip: surgical exclusion and anticoagulation do not obviate transesophageal echocardiography prior to cardioversion
por: Lo Presti, Saberio, et al.
Publicado: (2022)

Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports
por: Hlusi, Antonin, et al.
Publicado: (2015)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
por: Kuter, David J.
Publicado: (2022)

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)

The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Chen, Yuehong, et al.
Publicado: (2021)

Recalcitrant nodular scabies showing excellent response to tofacitinib: five case reports
por: Zhao, Yu-Kun, et al.
Publicado: (2023)

Isoniazid Causing Drug-Induced Thrombocytopenia
por: Laub, Donald R
Publicado: (2011)

Treatment-Refractory Central Centrifugal Cicatricial Alopecia Responsive to a Novel Botanical Treatment
por: Umar, Sanusi, et al.
Publicado: (2022)

A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag
por: Purushothaman, Jyothis, et al.
Publicado: (2016)

SEVERE/REFRACTORY IMMUNE THROMBOCYTOPENIA IN MILD COVID-19 DISEASE
por: MENON, TRISHALA, et al.
Publicado: (2021)

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
por: Rolf, Michael G, et al.
Publicado: (2015)

Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis
por: Chen, Yuehong, et al.
Publicado: (2022)

P1613: REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.
por: Moulis, Guillaume, et al.
Publicado: (2023)

Very Severe and Refractory Noninfectious Cystitis in Patients with Systemic Lupus Erythematosus: Potential Role of Rituximab Therapy
por: Ocampo-Piraquive, Vanessa, et al.
Publicado: (2021)

Atorvastatin-Induced Refractory Thrombocytopenia
por: Ghuman, Jasmine, et al.
Publicado: (2021)

Rituximab for refractory granulomatous eye disease
por: Lower, Elyse E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r0v4ran7v8thi6n5234e40shkh